CHOSA ltd. is developing a full-evidence model for response prediction of anticancer drugs using the most complex and recent information on the molecular response of cancer products. These data stem from proprietary and public databases and include a very rich description of the molecular composition and sensitivity of cell cultures exposed to various cancer drugs (omics).